SAN

82.45

-1.06%↓

MRK1

116.5

-0.98%↓

SHL.DE

42.92

-1.83%↓

ARGX

769.6

+0.05%↑

FRE

47.92

+1.91%↑

SAN

82.45

-1.06%↓

MRK1

116.5

-0.98%↓

SHL.DE

42.92

-1.83%↓

ARGX

769.6

+0.05%↑

FRE

47.92

+1.91%↑

SAN

82.45

-1.06%↓

MRK1

116.5

-0.98%↓

SHL.DE

42.92

-1.83%↓

ARGX

769.6

+0.05%↑

FRE

47.92

+1.91%↑

SAN

82.45

-1.06%↓

MRK1

116.5

-0.98%↓

SHL.DE

42.92

-1.83%↓

ARGX

769.6

+0.05%↑

FRE

47.92

+1.91%↑

SAN

82.45

-1.06%↓

MRK1

116.5

-0.98%↓

SHL.DE

42.92

-1.83%↓

ARGX

769.6

+0.05%↑

FRE

47.92

+1.91%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

19.16 4.93

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

17.92

Max

19.5

Põhinäitajad
By Trading Economics
Sissetulek	41M -5.4M
Müük	48M 27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	46M 1.1M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+25.41% upside

Turustatistika
By TradingEconomics
Turukapital	-25M 882M
Eelmine avamishind	14.23
Eelmine sulgemishind	19.16

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. dets 2025, 22:02 UTC

Tulu

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10. dets 2025, 21:46 UTC

Tulu

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10. dets 2025, 23:52 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10. dets 2025, 23:43 UTC

Market Talk

Nikkei May Rise After Fed Rate Cut -- Market Talk

10. dets 2025, 23:36 UTC

Market Talk

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10. dets 2025, 23:20 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10. dets 2025, 23:15 UTC

Tulu

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10. dets 2025, 22:59 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10. dets 2025, 22:45 UTC

Market Talk

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10. dets 2025, 22:40 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 22:06 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 22:02 UTC

Tulu

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10. dets 2025, 22:00 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10. dets 2025, 21:53 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10. dets 2025, 21:50 UTC

Market Talk

Tulu

Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

10. dets 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

10. dets 2025, 21:45 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10. dets 2025, 21:33 UTC

Tulu

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10. dets 2025, 21:32 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10. dets 2025, 21:28 UTC

Omandamised, ülevõtmised, äriostud

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10. dets 2025, 21:25 UTC

Tulu

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10. dets 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10. dets 2025, 21:16 UTC

Tulu

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10. dets 2025, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10. dets 2025, 21:15 UTC

Tulu

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10. dets 2025, 21:14 UTC

Tulu

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

25.41% tõus

12 kuu keskmine prognoos

Keskmine 23 EUR 25.41%

Kõrge 25 EUR

Madal 21 EUR

Põhineb 3 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.